We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+33.15%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$400M
AUM Growth
+$119M
Cap. Flow
+$47.5M
Cap. Flow %
11.87%
Top 10 Hldgs %
66.54%
Holding
29
New
10
Increased
11
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$23.7M
2
OFIX icon
Orthofix Medical
OFIX
+$15.6M
3
ENDP
Endo International plc
ENDP
+$15.3M
4
BIIB icon
Biogen
BIIB
+$13.4M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$10.9M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$21.5M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$19.9M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$12.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.1M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$9.85M

Sector Composition

Rank Sector Weight
1 Healthcare 49.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELGZ
26
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$111K 0.03%
+13,770
New +$106K
AMRN
27
Amarin Corp
AMRN
$299M
– –
-5,800
Closed -$673K
JAZZ icon
28
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-312,858
Closed -$21.5M
QCOR
29
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-200,000
Closed -$9.09M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Consonance Capital Management held 29 positions worth $400M, up 42% from $281M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Consonance Capital Management deployed $47.5M of net new capital in Q3 2013, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS: 1,001,514 shares worth $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 40% a quarter earlier.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $19.9M trimmed.

  • Consonance Capital Management's largest Q3 2013 buy was WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS: 1,001,514 shares worth $27.4M.
  • Consonance Capital Management added most to Taro Pharmaceutical Industries Ltd. in Q3 2013, an estimated $8.17M increase.
  • Consonance Capital Management's biggest Q3 2013 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $19.9M.
  • Consonance Capital Management fully exited Jazz Pharmaceuticals in Q3 2013, selling an estimated $21.5M.
  • Consonance Capital Management's ten largest holdings make up 67% of its $400M portfolio in Q3 2013.
  • Consonance Capital Management opened 10 new positions and closed 3 in Q3 2013.
  • Consonance Capital Management's portfolio value rose 42% quarter-over-quarter to $400M.

Based on Consonance Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.